CJC-1295 Ipamorelin is the most widely studied growth hormone secretagogue peptide combination in research, producing synergistic GH elevation through complementary receptor pathways for superior results.
The CJC-1295 Ipamorelin combination works because both peptides stimulate the body’s natural growth hormone (GH) production through different receptor systems — GHRH and ghrelin pathways respectively — creating a powerful synergistic effect when stacked together.
This guide covers the mechanisms, published research data, research protocols, and key differences between these two GH-releasing peptides, as well as how the CJC-1295 Ipamorelin stack compares to exogenous HGH.
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified version of the first 29 amino acids of GHRH (known as GRF 1-29 or Sermorelin). The modification involves replacing four amino acids to increase stability and resistance to enzymatic degradation.
CJC-1295 exists in two forms:
CJC-1295 without DAC (Modified GRF 1-29)
The version without Drug Affinity Complex has a shorter half-life of approximately 30 minutes. It produces pulsatile GH release that more closely mimics the body’s natural GH secretion pattern.
CJC-1295 with DAC
The DAC (Drug Affinity Complex) version binds to albumin in the bloodstream, extending the half-life to approximately 6–8 days. This produces sustained, elevated GH levels rather than pulsatile release. See the peptide half-life chart for comparison.
What Is Ipamorelin?
Ipamorelin is a pentapeptide (five amino acids) that acts as a selective growth hormone secretagogue receptor (GHS-R) agonist. Unlike earlier ghrelin mimetics like GHRP-6 and GHRP-2, Ipamorelin is highly selective — it stimulates GH release without significantly affecting cortisol, prolactin, or appetite (hunger).
This selectivity is Ipamorelin’s defining advantage in research. Earlier GHS-R agonists triggered multiple hormonal cascades, making it difficult to isolate the effects of GH elevation alone. Ipamorelin’s clean pharmacological profile allows more controlled experimental design.
Mechanism of Action: How CJC-1295 Ipamorelin Works at the Receptor Level
Understanding the dual-pathway mechanism of CJC-1295 Ipamorelin is essential for interpreting research findings. Each peptide acts on a distinct receptor population in the anterior pituitary, and their simultaneous activation produces effects that neither compound achieves alone.
CJC-1295 binds to the GHRH receptor (GHRHR) on pituitary somatotroph cells. This receptor is a G protein-coupled receptor (GPCR) that, when activated, triggers adenylyl cyclase, increases intracellular cAMP, and activates protein kinase A (PKA). The downstream result is increased transcription of GH genes, synthesis of new GH, and a larger releasable pool of GH stored within somatotrophs. In essence, CJC-1295 “loads the cannon” — it primes the pituitary with more GH available for release.
Ipamorelin acts through a completely different GPCR — the ghrelin receptor (GHS-R1a). When Ipamorelin binds GHS-R1a, it activates phospholipase C via Gq signaling, leading to IP3-mediated calcium release from intracellular stores. This calcium surge triggers exocytosis — the actual release of stored GH granules from somatotrophs into the bloodstream. Ipamorelin essentially “pulls the trigger” on GH release.
When researchers administer CJC-1295 Ipamorelin together, the two pathways act synergistically: CJC-1295 ensures a large pool of GH is available, while Ipamorelin maximizes the release of that pool. Published data suggests this dual-receptor activation can produce GH elevations 2–3 times greater than either peptide alone. The combination also preserves the natural negative feedback loop through somatostatin, which means GH cannot rise uncontrollably — a safety feature absent with exogenous HGH.
Why Researchers Combine CJC-1295 and Ipamorelin
The combination leverages two complementary GH release pathways:
| Feature | CJC-1295 (GHRH Analog) | Ipamorelin (GHS-R Agonist) |
|---|---|---|
| Receptor Target | GHRH receptor on pituitary somatotrophs | Ghrelin/GHS receptor on pituitary |
| GH Release Pattern | Amplifies GH pulse amplitude | Increases GH pulse frequency |
| Cortisol Impact | Minimal | None |
| Prolactin Impact | Minimal | None |
| Appetite Stimulation | None | Minimal (unlike GHRP-6) |
| Half-Life | ~30 min (no DAC) / 6-8 days (DAC) | ~2 hours |
Synergy mechanism: CJC-1295 primes the pituitary by activating GHRH receptors, increasing the amount of GH available for release. Ipamorelin then triggers the actual release through GHS receptors. The combined effect produces a significantly larger GH pulse than either peptide alone — research suggests the CJC-1295 Ipamorelin combination can produce GH elevations 2–3x greater than either peptide individually.
Published Research on CJC-1295 Ipamorelin
Several peer-reviewed studies have examined the components of the CJC-1295 Ipamorelin combination. While most published trials investigate each peptide independently, the mechanistic rationale for the combination is well-supported by the literature.
A key study published in the Journal of Clinical Endocrinology and Metabolism (Ionescu & Frohman, 2006) evaluated CJC-1295 (with DAC) in 66 healthy adult subjects. Researchers found that a single injection produced mean GH increases of 2–10 fold above baseline, with peak GH lasting 6 days. Critically, IGF-1 levels rose 1.5–3.0 fold above baseline and remained elevated for up to 28 days. This study demonstrated that CJC-1295 produced significantly more sustained GH elevation than Sermorelin while preserving normal GH pulsatility patterns. The dose-response relationship was linear, with no serious adverse events reported.
Ipamorelin’s selectivity profile was characterized in a landmark preclinical study by Raun et al. (1998), who demonstrated that unlike GHRP-6 and GHRP-2, Ipamorelin produced dose-dependent GH release without measurable increases in cortisol (ACTH), prolactin, or FSH at doses up to 500 mcg/kg in animal models. This selectivity was attributed to Ipamorelin’s unique binding characteristics at GHS-R1a, which limits signal transduction to GH-producing pathways only.
A 2008 randomized, double-blind, placebo-controlled trial investigated Ipamorelin’s effects on postoperative ileus in 60 patients who had undergone major abdominal surgery. The Ipamorelin group demonstrated statistically significant improvements in GI motility recovery (p < 0.05), suggesting GHS-R1a agonism has broader physiological relevance beyond simple GH secretion. This finding opened new research directions for the CJC-1295 Ipamorelin combination in recovery protocols.
Research published in Growth Hormone and IGF Research examined the dose-dependent relationship between GHRH analog administration and IGF-1 elevation across multiple study populations. Researchers found that GH secretagogue combinations reliably produced 40–80% increases in mean 24-hour GH concentrations compared to placebo, with IGF-1 responses of 20–45% above baseline after 12 weeks of administration. These data support the CJC-1295 Ipamorelin combination as an effective model for studying somatotropic axis function. See PubMed studies on Ipamorelin and growth hormone for the primary literature.
Research Applications of CJC-1295 Ipamorelin
Research on CJC-1295 Ipamorelin spans multiple areas, from body composition to recovery and longevity. Below are the key areas of scientific investigation.
Body Composition Research
GH elevation promotes lipolysis and lean mass preservation. The CJC-1295 Ipamorelin combination is studied for its effects on body composition without the supraphysiological GH levels associated with exogenous HGH administration. This distinguishes it from the direct fat-targeting mechanism of peptides like AOD-9604 and the appetite-modulating approach of GLP-1 peptides like Retatrutide.
Sleep and Recovery
GH is primarily released during deep sleep. Research into CJC-1295 Ipamorelin examines effects on sleep architecture and recovery markers. Ipamorelin’s lack of cortisol stimulation makes it particularly suitable for sleep-related research, as cortisol elevation would confound sleep quality measurements. Researchers studying peptides for sleep recovery often use the CJC-1295 Ipamorelin stack as a reference model due to its clean hormonal profile.
Anti-Aging and Longevity
Natural GH production declines approximately 14% per decade after age 30. The CJC-1295 Ipamorelin combination is studied as a means of restoring more youthful GH pulsatility patterns without replacing GH directly. This intersects with broader anti-aging peptide research, though the mechanisms differ from peptides like GHK-Cu which modulate gene expression directly.
Tissue Repair Augmentation
GH promotes protein synthesis and cellular regeneration. Some research protocols combine GH secretagogues with tissue repair peptides like BPC-157 and TB-500 to study whether elevated GH enhances the healing response. See the peptide stacking guide for more on combination protocols.
CJC-1295 Ipamorelin vs. Exogenous HGH
| Feature | CJC-1295 + Ipamorelin | Exogenous HGH |
|---|---|---|
| GH Source | Stimulates endogenous production | Replaces with synthetic GH |
| GH Pattern | Pulsatile (physiological) | Sustained elevation (supraphysiological) |
| Feedback Loop | Preserved — pituitary retains function | Suppressed — may reduce natural GH over time |
| IGF-1 Elevation | Moderate, proportional | Can be excessive |
| Side Effect Profile | Generally well-tolerated | Water retention, joint pain, insulin resistance |
| Controlled Substance | No — research peptides | Yes — prescription drug |
Research Protocols for CJC-1295 Ipamorelin Studies
Researchers investigating CJC-1295 Ipamorelin typically follow standardized preparation and administration protocols to ensure reproducibility. The following information reflects published research methodologies and laboratory best practices.
Reconstitution and Preparation
CJC-1295 Ipamorelin peptides are supplied as lyophilized powders. Standard reconstitution involves adding bacteriostatic water (BAC water) to the vial, directing the stream along the glass wall rather than directly onto the peptide cake to preserve structural integrity. For a 2 mg vial of CJC-1295 (no DAC) reconstituted with 2 mL of BAC water, the resulting concentration is 1 mg/mL (1,000 mcg/mL). See the detailed reconstitution guide for step-by-step instructions, and use the peptide calculator for concentration calculations.
Storage Conditions
Lyophilized (unreconstituted) CJC-1295 Ipamorelin vials should be stored at -20°C for long-term storage, or 2–8°C for periods up to 3 months. Once reconstituted, solutions remain stable at 2–8°C for 25–30 days when stored in low-bind polypropylene vials away from repeated freeze-thaw cycles. Researchers should consult comprehensive peptide storage protocols for temperature-controlled environments. Signs of peptide degradation include cloudiness, particulate matter, or unexpected color changes — see the guide on how to tell if a peptide has degraded.
Research Timing Considerations
Published research on CJC-1295 Ipamorelin typically administers the combination in the context of natural GH secretion rhythms. Since GH is predominantly released during slow-wave sleep (approximately 11 PM–1 AM), many research protocols time administration to coincide with this window to amplify endogenous pulses rather than override them. Research also frequently examines fasted-state administration, as elevated insulin suppresses GH secretion via somatostatin, which would attenuate the peptide combination’s effects.
Dose-Response Considerations in Published Literature
The dose-response data for CJC-1295 suggests a non-linear relationship at higher concentrations. The Ionescu & Frohman 2006 study found that doses between 30–60 mcg/kg produced the most favorable GH-to-side-effect ratio, with diminishing returns at higher concentrations. Ipamorelin research similarly shows that doses above a threshold (~200–300 mcg in most protocols) produce minimal additional GH release, as the releasable GH pool becomes the limiting factor — which is precisely where CJC-1295’s GHRH receptor priming becomes critical for the CJC-1295 Ipamorelin combination’s superior efficacy.
Safety Profile of CJC-1295 Ipamorelin in Research
Research on the CJC-1295 Ipamorelin combination has documented a favorable tolerability profile in published trials. Understanding the adverse event data is important for proper experimental design and result interpretation.
In the Ionescu & Frohman CJC-1295 phase 2 trial, the most commonly reported adverse events were transient injection site reactions (erythema, pain) in approximately 20% of subjects, and mild flushing or “GH flush” sensations in 15% of subjects. These were generally mild and self-limiting, resolving within 30–60 minutes. No serious adverse events attributable to CJC-1295 were reported across the 66 enrolled subjects over 56 days of observation.
Ipamorelin’s safety profile is characterized by its GH selectivity. Unlike GHRP-6 (which raises cortisol by up to 52% and ACTH by 61% in some studies), Ipamorelin produces no statistically significant changes in cortisol, prolactin, FSH, LH, or TSH at research-relevant doses. Water retention — a common side effect with exogenous GH — is minimal with CJC-1295 Ipamorelin because the peptide combination produces proportional, feedback-regulated IGF-1 elevation rather than sustained supraphysiological levels.
Researchers should note that GH peptides are not appropriate for subjects with active malignancy, and that elevated GH and IGF-1 may affect insulin sensitivity. Standard pre-research screening and monitoring protocols apply. For a comprehensive overview of adverse events across the peptide class, see the peptide side effects research guide.
How CJC-1295 Ipamorelin Compares to Other Growth Hormone Peptides
Researchers selecting a GH secretagogue protocol often consider several alternatives to the CJC-1295 Ipamorelin combination. Understanding how these compounds differ helps contextualize the research literature and design appropriate comparison studies.
CJC-1295 Ipamorelin vs. Sermorelin
Sermorelin is the original GHRH(1-29) analog and the most direct predecessor to CJC-1295. Both peptides activate the same GHRH receptor, but CJC-1295 incorporates four amino acid substitutions that dramatically improve metabolic stability. In research models, Sermorelin has a half-life of approximately 10–12 minutes due to rapid DPP-IV cleavage, while CJC-1295 (no DAC) achieves ~30 minutes. This difference translates to more reproducible peak GH measurements in timed research protocols. The CJC-1295 Ipamorelin combination is generally preferred over Sermorelin-based stacks in published studies because the improved stability produces more consistent GH pulse data.
CJC-1295 Ipamorelin vs. GHRP-6 / GHRP-2
GHRP-6 and GHRP-2 were the first GHS-R agonists studied in combination with GHRH analogs. They produce robust GH release but lack Ipamorelin’s selectivity — GHRP-6 raises cortisol by approximately 52% and increases appetite significantly, while GHRP-2 elevates prolactin. These off-target effects complicate experimental design and reduce the interpretability of body composition and recovery data. Ipamorelin was specifically developed to address this limitation. Published comparisons consistently show that CJC-1295 Ipamorelin protocols produce equivalent or superior GH elevation to CJC-1295 + GHRP-6 combinations while generating a cleaner hormonal signal — making CJC-1295 Ipamorelin the preferred research model when GH-specific effects need to be isolated.
CJC-1295 Ipamorelin vs. MK-677 (Ibutamoren)
MK-677 is an orally bioavailable GHS-R agonist that shares Ipamorelin’s receptor target but differs significantly in pharmacokinetics and selectivity. MK-677’s 24-hour half-life produces continuous GH and IGF-1 elevation rather than pulsatile release, which some researchers find useful for sustained IGF-1 studies but which also increases appetite and can elevate cortisol and prolactin over time. The CJC-1295 Ipamorelin injection-based combination produces more physiological pulsatile GH patterns and avoids the chronic GHS-R1a desensitization observed with continuous MK-677 administration. Researchers studying the effects of MK-677 should note this distinction when comparing results across protocols.
Handling and Storage
CJC-1295 Ipamorelin peptides are supplied as lyophilized powders requiring reconstitution with bacteriostatic water. Standard peptide storage protocols apply: store lyophilized vials at -20°C for long-term or 2–8°C for shorter periods. Reconstituted solutions should be refrigerated at 2–8°C and used within 25–30 days. Use the peptide calculator for concentration calculations.
Further Reading
For additional peer-reviewed research on CJC-1295 Ipamorelin and growth hormone secretagogues, researchers can consult PubMed studies on Ipamorelin and growth hormone, the CJC-1295 GHRH literature on PubMed, and NIH resources on growth hormone physiology. For context on how this CJC-1295 Ipamorelin research fits within the broader peptide landscape, see the complete guide to peptides and the CJC-1295 Ipamorelin growth hormone guide.
Understanding CJC-1295 Ipamorelin is essential for researchers navigating this rapidly evolving field in 2026. The combination’s dual-receptor mechanism, documented safety profile, and well-characterized dose-response relationship make it one of the most studied CJC-1295 Ipamorelin research models available to investigators today.
Frequently Asked Questions
What’s the difference between CJC-1295 with DAC and without DAC?
CJC-1295 without DAC (Modified GRF 1-29) has a ~30-minute half-life and produces pulsatile GH release mimicking natural physiology. CJC-1295 with DAC extends the half-life to 6–8 days through albumin binding, creating sustained GH elevation. Most research protocols for the CJC-1295 Ipamorelin combination use the non-DAC version because pulsatile release is considered more physiological.
Can CJC-1295/Ipamorelin be combined with healing peptides?
Yes. Research protocols sometimes combine CJC-1295 Ipamorelin with tissue repair peptides like BPC-157, TB-500, and GHK-Cu. The theoretical basis is that elevated GH may enhance the healing cascade by promoting protein synthesis and cellular regeneration.
Does Ipamorelin increase appetite like GHRP-6?
No. Ipamorelin is selective for GH release and does not significantly stimulate appetite, cortisol, or prolactin. This is one of its primary advantages over earlier GHS-R agonists like GHRP-6 and GHRP-2 that triggered multiple hormonal pathways. It is this selectivity that makes Ipamorelin the preferred partner in the CJC-1295 Ipamorelin research stack.
Is CJC-1295 the same as Sermorelin?
They are related but not identical. Both are GHRH analogs based on the first 29 amino acids of GHRH. CJC-1295 has four amino acid substitutions that increase stability and resistance to DPP-IV enzyme degradation, giving it a longer duration of action than Sermorelin. For research requiring more sustained GHRH pathway activation, CJC-1295 Ipamorelin is generally preferred over Sermorelin-based protocols.
How do growth hormone peptides compare to GLP-1 peptides?
They serve completely different research purposes. GH secretagogues like the CJC-1295 Ipamorelin stack stimulate growth hormone production for body composition, recovery, and anti-aging research. GLP-1 agonists like Retatrutide and semaglutide target metabolic pathways related to appetite and glucose regulation.
What purity standards should researchers look for in CJC-1295 Ipamorelin?
Research-grade CJC-1295 Ipamorelin should be verified by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to confirm both purity and molecular identity. Published research typically requires ≥98% purity for controlled experiments. Researchers should always request and review the certificate of analysis (COA) for every batch — see the guide on how to read a peptide COA for detailed guidance on interpreting purity data.
All PSPeptides products are sold exclusively for research and laboratory use.